Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHSM7I)

Drug Name
Cilomilast Drug Info
Synonyms
Ariflo; CIO; SB 207499; SB207499; Ariflo (TN); Cilomilast [USAN:INN]; SB-207499; Ariflo, SB-207499,Cilomilast; Cilomilast (JAN/USAN/INN); CIS-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLIC ACID; Cis-4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-Cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-4-cyanocyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Bronchitis CA20 Discontinued in Phase 3 [1]
Chronic obstructive pulmonary disease CA22 Discontinued in Phase 3 [1]
Emphysema CA21 Discontinued in Phase 3 [1]
Cross-matching ID
PubChem CID
151170
ChEBI ID
CHEBI:94683
CAS Number
CAS 153259-65-5
TTD Drug ID
DMHSM7I

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Phosphodiesterase 4 (PDE4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [5]
Oxtriphylline DMLHSE3 Cough MD12 Approved [6]
Roflumilast DMPGHY8 Asthma CA23 Approved [7]
Ibudilast DM4LSPN Castleman's disease 4B2Y Approved [8]
crisaborole DMNVKU6 Atopic dermatitis EA80 Approved [9]
Arofylline DM84AD1 Chronic obstructive pulmonary disease CA22 Phase 3 [2]
ARQ-151 DML61S4 Atopic dermatitis EA80 Phase 3 [10]
SUN13834 DMPK34E Gram-positive bacterial infection 1B74-1G40 Phase 2 [11]
ONO-6126 DMRT28X Chronic obstructive pulmonary disease CA22 Phase 2 [2]
E6005 DM1S489 Atopic dermatitis EA80 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Phosphodiesterase 4A (PDE4A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dyphylline DM8DZC1 Acute bronchial asthma CA23 Approved [11]
Enprofylline DMFYZKN Asthma CA23 Approved [13]
DENBUFYLLINE DM2R15Q Cognitive impairment 6D71 Phase 3 [14]
SOTB07 DMIG4OX Asthma CA23 Phase 3 [15]
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [16]
AN-2898 DMDK7CL Atopic dermatitis EA80 Phase 2 [17]
GPD-1116 DMOQ7YI Asthma CA23 Phase 2 [18]
TA-7906 DMZTAJL Atopic dermatitis EA80 Phase 2 [19]
HT-0712 DM2WP8F Cognitive impairment 6D71 Phase 2 [15]
TOFIMILAST DMLCUAS Chronic obstructive pulmonary disease CA22 Phase 2 [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interferon gamma (IFNG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amphotericin B DMTAJQE Acne vulgaris ED80 Approved [21]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [22]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [23]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [24]
Methotrexate DM2TEOL Anterior urethra cancer Approved [25]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [26]
Quercetin DM3NC4M Obesity 5B81 Approved [27]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [28]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [29]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-4 (IL4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [31]
Imiquimod DM1TMA3 Alopecia areata ED70.2 Approved [32]
Tolnaftate DM28MU7 Dermatophytosis 1F28.2 Approved [33]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [34]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [35]
Prednisone DM2HG4X Acute asthma CA23 Approved [36]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [24]
Methotrexate DM2TEOL Anterior urethra cancer Approved [25]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [26]
Cladribine DM3JDRP Hairy cell leukaemia 2A82.2 Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-5 (IL5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [22]
Tolnaftate DM28MU7 Dermatophytosis 1F28.2 Approved [33]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [34]
Prednisone DM2HG4X Acute asthma CA23 Approved [38]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [39]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [40]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [41]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [42]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [43]
Lindane DMB8CNL Infestations of lice and scabies 1G00.Z Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [45]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [46]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [47]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [48]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [49]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [50]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [51]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [52]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [53]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 3',5'-cyclic-AMP phosphodiesterase 4C (PDE4C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [55]
Quercetin DM3NC4M Obesity 5B81 Approved [56]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [57]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [58]
Roflumilast DMPGHY8 Asthma CA23 Approved [59]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [60]
Arsenic DMTL2Y1 N. A. N. A. Approved [61]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [62]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [63]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [64]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [65]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [66]
Panobinostat DM58WKG Chronic graft versus host disease Approved [67]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [68]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [69]
Leflunomide DMR8ONJ Arthritis FA20 Approved [70]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [50]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [71]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [72]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [58]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 4 (PDE4) TTV5CGO NOUNIPROTAC Inhibitor [2]
Phosphodiesterase 4A (PDE4A) TTZ97H5 PDE4A_HUMAN Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B) OTOA8WU2 PDE4B_HUMAN Gene/Protein Processing [4]
3',5'-cyclic-AMP phosphodiesterase 4C (PDE4C) OTI8VMHZ PDE4C_HUMAN Gene/Protein Processing [4]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Gene/Protein Processing [4]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Protein Interaction/Cellular Processes [4]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Protein Interaction/Cellular Processes [4]
Interleukin-5 (IL5) OTAFPSCO IL5_HUMAN Protein Interaction/Cellular Processes [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7407).
2 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
3 Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
4 Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities. J Pharmacol Exp Ther. 2002 Apr;301(1):241-8. doi: 10.1124/jpet.301.1.241.
5 Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
8 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
9 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
10 Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.
11 Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
12 Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.
13 Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62.
14 Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
16 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
17 An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
18 Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
19 Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
20 GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54.
21 Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
22 Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31. doi: 10.1089/107999003322277838.
23 Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Res. 2007 Jul;75(1):36-42. doi: 10.1016/j.antiviral.2006.11.008. Epub 2006 Dec 13.
24 Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother. 2005 Sep;56(3):502-6. doi: 10.1093/jac/dki251. Epub 2005 Jul 8.
25 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
26 Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
27 The flavonoid, quercetin, differentially regulates Th-1 (IFNgamma) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. Biochim Biophys Acta. 2002 Dec 16;1593(1):29-36. doi: 10.1016/s0167-4889(02)00328-2.
28 [Effects of vitamin A on the differentiation, maturation and functions of dendritic cells from cord blood]. Zhonghua Er Ke Za Zhi. 2004 May;42(5):340-3.
29 Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. Chemotherapy. 1998 May-Jun;44(3):174-80. doi: 10.1159/000007112.
30 Detection of Drug-Responsive T-Lymphocytes in a Case of Fatal Antituberculosis Drug-Related Liver Injury. Chem Res Toxicol. 2016 Nov 21;29(11):1793-1795. doi: 10.1021/acs.chemrestox.6b00393. Epub 2016 Nov 9.
31 Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells. Eur Respir J. 1999 Nov;14(5):1106-12. doi: 10.1183/09031936.99.14511069.
32 Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
33 Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. J Invest Dermatol. 2001 Dec;117(6):1635-46. doi: 10.1046/j.0022-202x.2001.01566.x.
34 Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999 Mar;30(3):376-82. doi: 10.1016/s0168-8278(99)80093-2.
35 Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood. 2001 Mar 15;97(6):1742-9. doi: 10.1182/blood.v97.6.1742.
36 Immune responses in autoimmune hepatitis: effect of prednisone and azathioprine treatment: case report. Int J Med Sci. 2009 Jun 30;6(4):177-83. doi: 10.7150/ijms.6.177.
37 Paradoxical immunologic effects of 2-CdA therapy: comment on the article by Davis et al. Arthritis Rheum. 1998 Sep;41(9):1704-5. doi: 10.1002/1529-0131(199809)41:9<1704::AID-ART26>3.0.CO;2-9.
38 Cytokine abnormalities in a patient with eosinophilic fasciitis. Ann Allergy Asthma Immunol. 2003 Apr;90(4):452-5. doi: 10.1016/S1081-1206(10)61832-7.
39 Expression of PPARgamma in eosinophils and its functional role in survival and chemotaxis. Immunol Lett. 2003 Apr 3;86(2):183-9. doi: 10.1016/s0165-2478(03)00003-8.
40 Direct and indirect effects of retinoic acid on human Th2 cytokine and chemokine expression by human T lymphocytes. BMC Immunol. 2006 Nov 21;7:27. doi: 10.1186/1471-2172-7-27.
41 Glucosamine improved atopic dermatitis-like skin lesions in NC/Nga mice by inhibition of Th2 cell development. Scand J Immunol. 2011 Jun;73(6):536-45. doi: 10.1111/j.1365-3083.2011.02526.x.
42 Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol. 2002 Dec;133(1-2):124-31. doi: 10.1016/s0165-5728(02)00370-3.
43 IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A. Int Immunol. 1995 Mar;7(3):449-57. doi: 10.1093/intimm/7.3.449.
44 Limited effect of selected organic pollutants on cytokine production by peripheral blood leukocytes. Eur Cytokine Netw. 2004 Apr-Jun;15(2):145-51.
45 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
46 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
47 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
48 Histamine up-regulates phosphodiesterase 4 activity and reduces prostaglandin E2-inhibitory effects in human neutrophils. Inflamm Res. 2000 Nov;49(11):600-9. doi: 10.1007/s000110050637.
49 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
50 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
51 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
52 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
53 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
54 In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
55 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
56 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
57 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
58 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
59 Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J Pharmacol Exp Ther. 2005 Aug;314(2):846-54. doi: 10.1124/jpet.105.083519. Epub 2005 May 18.
60 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
61 Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
62 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
63 Identification of transcriptional biomarkers induced by SERMS in human endometrial cells using multivariate analysis of DNA microarrays. Biomarkers. 2004 Nov-Dec;9(6):447-60.
64 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
65 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
66 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
67 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
68 Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
69 Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
70 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
71 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
72 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.